Serial Dried Blood Spot C-Peptide Sampling, but Not Urine C-Peptide–to–Creatinine Ratio, Detects Early Preservation of β-Cell Function in New-Onset Type 1 Diabetes: Experience From the USTEKID Trial
Diabetes Care · 01.07.2026 · 49 (7) · 1213-1220
DOI: 10.2337/dc25-2896 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 12.05.2026. Verfasst von Gareth J Dunseath und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Group, Swansea University Medical School, Swansea, U.K. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, C-Peptide, Insulin-Secreting Cells, Creatinine. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Diabetes UK, Breakthrough T1D.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To determine whether less invasive C-peptide tests, urine C-peptide–to–creatinine ratio (UCPCR) and dried blood spot (DBS), could replace the mixed-meal tolerance test (MMTT) in the context of an interventional clinical trial (Ustekinumab in Adolescents With Recent-Onset Type 1 Diabetes [USTEKID]). RESEARCH DESIGN AND METHODS C-peptide was assessed at screening and weeks 28 and 52 using a 2-h MMTT. UCPCR samples were taken after each MMTT. Fasting and 60-min postmeal DBS samples were collected weekly to week 28 and then monthly to week 52. UCPCR and glucose-adjusted DBS results were compared with MMTT results. Weekly DBS averages were calculated and differences between treatment groups assessed using a mixed linear model, bootstrap one-sample t tests, and autoregressive integrated moving averages. Six months of weekly DBS data were used to predict 12-month C-peptide levels. RESULTS Unlike MMTT C-peptide, UCPCR did not change in the first 6 months, before decreasing by 12 months. The DBS area under the curve from 0 to 60 min declined steadily over 12 months. The DBS C-peptide decline in the intervention group was significantly less than that in the control group by week 20 (P < 0.05). This was not apparent with UCPCR and did not become evident until 52 weeks with MMTT. The slope from 6 months of DBS could predict 12-month MMTT C-peptide in the control but not in the intervention group, consistent with the increasing impact of the intervention from 6 to 12 months indicated by the MMTT data. CONCLUSIONS Frequently sampled glucose-adjusted DBS was more sensitive to early change than MMTT and could serve as a home-based marker of β-cell function, whereas UCPCR was not sensitive to change in the early period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes Research Group, Swansea University Medical School, Swansea, U.K.
- Swansea Trials Unit, Swansea University Medical School, Swansea, U.K.
- Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, U.K.
- Division of Population Medicine, Cardiff University School of Medicine, Cardiff, U.K.
ORCID-Profile: Gareth J Dunseath, Colin M Dayan
Förderung
- Diabetes UK
- Breakthrough T1D
Zitieren
APA
Dunseath, G. J., Cheung, W. Y., Luzio, S. D., Carter, K., Tatovic, D., Taylor, P. N., Gregory, J. W., & Dayan, C. M. (2026). Serial Dried Blood Spot C-Peptide Sampling, but Not Urine C-Peptide–to–Creatinine Ratio, Detects Early Preservation of β-Cell Function in New-Onset Type 1 Diabetes: Experience From the USTEKID Trial. Diabetes Care, 49(7), 1213-1220. https://doi.org/10.2337/dc25-2896
Vancouver
Dunseath GJ, Cheung WY, Luzio SD, Carter K, Tatovic D, Taylor PN, et al. Serial Dried Blood Spot C-Peptide Sampling, but Not Urine C-Peptide–to–Creatinine Ratio, Detects Early Preservation of β-Cell Function in New-Onset Type 1 Diabetes: Experience From the USTEKID Trial. Diabetes Care. 2026;49(7):1213-1220. doi:10.2337/dc25-2896
BibTeX
@article{Dunseath2026,
author = {Dunseath, Gareth J and Cheung, Wai-Yee and Luzio, Stephen D and Carter, Kym and Tatovic, Danijela and Taylor, Peter N and Gregory, John W and Dayan, Colin M},
title = {Serial Dried Blood Spot C-Peptide Sampling, but Not Urine C-Peptide–to–Creatinine Ratio, Detects Early Preservation of β-Cell Function in New-Onset Type 1 Diabetes: Experience From the USTEKID Trial},
journal = {Diabetes Care},
year = {2026},
volume = {49},
number = {7},
pages = {1213--1220},
doi = {10.2337/dc25-2896}
}
EUVIMED